



## Appendix 4. Supplemental Figures


**Appendix 4: Supplemental Figures**




**Appendix Figure 1.** Percent bias removed for each scenario and variable selection method when matching on the estimated propensity scores. Plots A, B, and C show results for plasmode simulations based on the NSAID, NOAC, and Statin datasets, respectively.



**Appendix Figure 2.** Percent bias removed for each scenario and variable selection method when using IPTW to implement the estimated propensity scores. Plots A, B, and C show results for plasmode simulations based on the NSAID, NOAC, and Statin datasets, respectively.




**Appendix Figure 3.** Percent bias removed for each scenario and variable selection method when using TMLE to implement the estimated propensity scores. Plots A, B, and C show results for plasmode simulations based on the NSAID, NOAC, and Statin datasets, respectively.






**Appendix Figure 4.** Mean squared error (MSE) for each scenario and variable selection method when matching on the estimated propensity scores. Plots A, B, and C show results for plasmode simulations based on the NSAID, NOAC, and Vytorin datasets, respectively.





**Appendix Figure 5.** Mean squared error (MSE) for each scenario and variable selection method when using IPTW to implement the estimated propensity scores. Plots A, B, and C show results for plasmide simulations based on the NSAID, NOAC, and Vytorin datasets, respectively.



**Appendix Figure 6.** Mean squared error (MSE) for each scenario and variable selection method when using TMLE to implement the estimated propensity scores. Plots A, B, and C show results for plasmide simulations based on the NSAID, NOAC, and Vytorin datasets, respectively.